NCT06837896CompletedPhase 3
Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
A Multicenter Study Evaluating the Efficacy and Safety of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 111 (actual)
- First submitted
- 17 Feb 2025
- Start date
- 11 Mar 2025
- Primary completion date
- 15 Jan 2026
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Diseases
- Prostate cancer
- NCT number
- NCT06837896
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 111
- From 11 Mar 2025 to the primary completion date, 15 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have previously undergone pituitectomy or adrenalectomy or have pituitary disease or adrenal dysfunction;
- Those who have had any prostate surgery within 4 weeks prior to initial dosing or prostate surgery or other major surgical treatment during the planned trial period (except urinary tract obstruction relief);
Other illness
- Diagnosed or suspected of hormone-resistant prostate cancer;
- For prostate cancer patients who have had or are undergoing endocrine therapy
Other
- The imaging results of screening visits clearly showed the presence of brain metastases;
Who the study is looking for
- 1\. Histological or cytological diagnosis of prostate cancer;；
- Advanced prostate cancer patients eligible for endocrine therapy, able to receive continuous androgen deprivation therapy for at least 6 months.
- Serum testosterone ≥150 ng/dL (5.2nmol/L) at screening visit;
- The Eastern Cooperative Oncology Group (ECOG) score is 0 to 1.
Age in the registry: 18 years to - · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| No. 8888 Lvyou Road Coordinator of this site? Confirm its status | Jinan | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.